Alopecia associated with ingestion of amphetamines has been reported occasionally. These drugs may act as a triggering factor to develop diffuse alopecia. We present a case of alopecia areata possibly linked to the ingestion of amphetamines. This case may provide evidence that amphetamines can also be a cause of alopecia areata in susceptible individuals. We intend to awaken an interest in the medication history of patients presenting with sudden diffuse alopecia areata.
INTRODUCTION
A lopecia related to the ingestion of amphetamines has been reported as early as 1965 with amphetamines or amphetamine-like drugs. [1] Some authors even suggest that the sole discontinuation of the drug can lead to regrowth of the hair. [2] There is little information linking the ingestion of these drugs as a triggering factor to develop alopecia. We present a case of alopecia areata possibly linked to the ingestion of amphetamines.
Case Report
A 50-year-old Hispanic female presented to the clinic with a 15-day history of diffuse alopecia. Her medical history was relevant to obesity for which she had been taking clobenzorex in the last 5 months (Itravil AP, 60 mg a day). The rest of her medical record was unremarkable. Laboratory workup and a biopsy were required. Her diagnosis was compatible with alopecia areata. Initial levels of Vitamin D and ferritin were 8 ng/mL and 25 ng/mL, respectively. She was then treated with oral mini-pulses of dexamethasone and azathioprine 100 mg as a steroid-sparing agent. Improvement was observed within a month of starting therapy. According to the Naranjo algorithm, our patient suffered a probable adverse drug reaction (5 points) to clobenzorex [ Figure 1 ].
Amphetamines or amphetamine-like drugs have been prescribed for obesity, narcolepsy, as well as for pediatric disorders such as Attention Deficit/Hyperactivity Disorder (ADHD). The earliest report of alopecia secondary to the use of amphetamines was described as "diffuse thinning of hair on the vertex" in 1988 by Voron. [1] Another study regarding amphetamines and obesity with 2370 subjects reported nonclassified alopecia (1.7%) as a side effect. [3] Testing of lisdexamfetamine in adults mentioned an unclassified alopecia in one subject. [4] This drug was also responsible for a generalized alopecia in a 5-year-old girl treated for ADHD 5 days after starting treatment.
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Her hair loss ceased 2 days after stopping medication. [5] Dextroamphetamine ingestion was associated with a sudden rapid loss of almost all body hair in a 57-year-old female with a long history of narcolepsy. [1] These reports may suggest a possible relation of amphetamine use with the development of alopecia. Some authors have stated that there is no causal relationship between the use of psychotropic medications and alopecia, because also rapid weight loss can contribute to it. [2] 
CONCLUSION
The occurrence of this alopecia areata associated with the intake of clobenzorex (amphetamine) provides more evidence on the possible causality of ingestion of amphetamines and alopecia. This case intends to awaken an interest in the medication history of patients presenting with sudden diffuse alopecia areata that could possibly be associated with the intake of weight-losing medication, specifically amphetamines.
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